Paper published in Nature Scientific Reports shows that Cofactor’s multianalyte biomarkers based on T cell subtype profiling (TCSP) predicted patient response to anti-PD-1 therapy in three different cancers (lung cancer, melanoma, and head and neck).
San Francisco, California--(Newsfile Corp. - February 15, 2022) - Cofactor Genomics today announced publication in the latest issue of Nature Scientific Reports of a study showing that the company’s multianalyte biomarkers based on T cell subtype profiling (TCSP) predicted patient response to anti-PD-1 therapy in three different cancers (lung cancer, melanoma, and head and neck) and outperformed the indicated PD-L1 test and Tumor Mutational Burden.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Paper published in Nature Scientific Reports shows that Cofactor’s multianalyte biomarkers based on T cell subtype profiling (TCSP) predicted patient response to anti-PD-1 therapy in three different cancers (lung cancer, melanoma, and head and neck).
- Cofactor’s approach also was shown to outperform the indicated PD-L1 test and Tumor Mutational Burden.
- Method shows promise as a pan-cancer, anti-PD1 prediction platform.
Click image above to view full announcement.
About Cofactor Genomics
Cofactor Genomics is on a mission to close the Precision Medicine Gap through Predictive Immune Modeling. Cofactor has leveraged its experience as one of the first CAP-certified, clinical RNA sequencing laboratories to develop new methods that accurately and holistically characterize disease. Instead of searching for isolated, single-analyte biomarkers, Cofactor’s products create multidimensional biomarkers that better capture the complex immune response. Cofactor has spent years pioneering the molecular and machine learning tools to build a database of Health Expression Models, now integrated into our multidimensional diagnostics. Cofactor Genomics empowers clinicians to be better informed while making treatment decisions to improve patient outcomes.
Contacts:
Michelle McAdam, Chronic Communications Inc.
(310) 902-1274
michelle@chronic-comm.com
Source: Cofactor Genomics
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/113852
